Abstract
Many enzymes and proteins are regulated by their quaternary structure and/or by their association in homoand/ or hetero-oligomer complexes. Thus, these protein-protein interactions can be good targets for blocking or modulating protein function therapeutically. The large number of oligomeric structures in the Protein Data Bank (http://www.rcsb. org/) reflects growing interest in proteins that function as multimeric complexes. In this review, we consider the particular case of homodimeric enzymes as drug targets. There is intense interest in drugs that inhibit dimerization of a functionally obligate homodimeric enzyme. Because amino acid conservation within enzyme interfaces is often low compared to conservation in active sites, it may be easier to achieve drugs that target protein interfaces selectively and specifically. Two main types of dimerization inhibitors have been developed: peptides or peptidomimetics based on sequences involved in protein-protein interactions, and small molecules that act at hot spots in protein-protein interfaces. Examples include inhibitors of HIV protease and HIV integrase. Studying the mechanisms of action and locating the binding sites of such inhibitors requires different techniques for different proteins. For some enzymes, ligand binding is only detectable in vivo or after unfolding of the complexes. Here, we review the structural features of dimeric enzymes and give examples of inhibition through interference in dimer stability. Several techniques for studying these complex phenomena will be presented.
Keywords: Homodimeric enzyme, dimeric proteins, drug target, protein-protein interactions, inhibitors design, dissociative inhibition model
Current Medicinal Chemistry
Title: Homodimeric Enzymes as Drug Targets
Volume: 17 Issue: 9
Author(s): D. Cardinale, O. M.H. Salo-Ahen, S. Ferrari, G. Ponterini, G. Cruciani, E. Carosati, A. M. Tochowicz, S. Mangani, R. C. Wade and M. P. Costi
Affiliation:
Keywords: Homodimeric enzyme, dimeric proteins, drug target, protein-protein interactions, inhibitors design, dissociative inhibition model
Abstract: Many enzymes and proteins are regulated by their quaternary structure and/or by their association in homoand/ or hetero-oligomer complexes. Thus, these protein-protein interactions can be good targets for blocking or modulating protein function therapeutically. The large number of oligomeric structures in the Protein Data Bank (http://www.rcsb. org/) reflects growing interest in proteins that function as multimeric complexes. In this review, we consider the particular case of homodimeric enzymes as drug targets. There is intense interest in drugs that inhibit dimerization of a functionally obligate homodimeric enzyme. Because amino acid conservation within enzyme interfaces is often low compared to conservation in active sites, it may be easier to achieve drugs that target protein interfaces selectively and specifically. Two main types of dimerization inhibitors have been developed: peptides or peptidomimetics based on sequences involved in protein-protein interactions, and small molecules that act at hot spots in protein-protein interfaces. Examples include inhibitors of HIV protease and HIV integrase. Studying the mechanisms of action and locating the binding sites of such inhibitors requires different techniques for different proteins. For some enzymes, ligand binding is only detectable in vivo or after unfolding of the complexes. Here, we review the structural features of dimeric enzymes and give examples of inhibition through interference in dimer stability. Several techniques for studying these complex phenomena will be presented.
Export Options
About this article
Cite this article as:
Cardinale D., Salo-Ahen M.H. O., Ferrari S., Ponterini G., Cruciani G., Carosati E., Tochowicz M. A., Mangani S., Wade C. R. and Costi P. M., Homodimeric Enzymes as Drug Targets, Current Medicinal Chemistry 2010; 17 (9) . https://dx.doi.org/10.2174/092986710790712156
DOI https://dx.doi.org/10.2174/092986710790712156 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety and Efficacy of Mavrilimumab For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Current Rheumatology Reviews Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets Dry Emulsions based on Alpha Cyclodextrin and Vegetable Oils for Buccal Delivery of Lipophilic Drugs
Drug Delivery Letters Potential of Lung Surfactant Proteins, SP-A and SP-D, and Mannan Binding Lectin for Therapy and Genetic Predisposition to Allergic and Invasive Aspergillosis
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: Paracrine Mechanisms, Signaling and Epigenetics in Repairing Damaged Tissue]
Recent Patents on Regenerative Medicine The Interleukin-17/Interleukin-22 Innate Axis in the Gut as a New Drug Target in Allergic-Inflammatory and Autoimmune Diseases. A Working Hypothesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets New Insights on the Antitumoral Properties of Prodiginines
Current Medicinal Chemistry Inhibitors of Phosphoinositol 3 Kinase and NFκB for the Treatment of Chronic Obstructive Pulmonary Disease
Recent Patents on Inflammation & Allergy Drug Discovery Risk Scores for Patients with Chest Pain: Evaluation in the Emergency Department
Current Cardiology Reviews Socioeconomic Status: The Missing Link Between Obesity and Diabetes Mellitus?
Current Diabetes Reviews Inflammatory Biomarkers in Peripheral Artery Disease: Diagnosis, Prognosis, and Therapeutic Challenges
Current Medicinal Chemistry Roles of Chemokine CXCL12 and its Receptors in Ischemic Stroke
Current Drug Targets Pathogenesis of Acute Kidney Injury During Sepsis
Current Drug Targets Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Absorption, Disposition and Pharmacokinetics of Nanoemulsions
Current Drug Metabolism Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Editorial: Advances in the Treatment of Neurodegenerative Diseases and Epilepsy
Current Pharmaceutical Design Applications of Animal Models of Infectious Arthritis in Drug Discovery:A focus on Alphaviral Disease
Current Drug Targets Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets